FAD-dependent enzymes involved in the metabolic oxidation of xenobiotics;Enzymes FAD-dépendantes impliquées dans l'oxydation métabolique des xénobiotiques

Annales Pharmaceutiques Francaises

Volumn 69, Issue 1, 2011, Pages 45-52

  Strolin Benedetti, M ^a  

^a UCB PHARMA   (Belgium)

Author keywords

Aldehyde oxidase; Flavin containing monooxygenases; Molybdenum hydroxylases; Monoamine oxidases; Polyamine oxidases; Xanthine oxidase

Indexed keywords

6 DEOXYPENCICLOVIR; ALDEHYDE OXIDASE; ALMOXATONE; AMINE OXIDASE (FLAVIN CONTAINING); CIMETIDINE; CISAPRIDE; CITALOPRAM; CLOZAPINE; CYTOCHROME P450 3A4; DIMETHYLANILINE MONOOXYGENASE; DOCARPAMINE; DRUG METABOLIZING ENZYME; FAMCICLOVIR; IBOPAMINE; ITOPRIDE; LAZABEMIDE; MOLYBDENUM HYDROXYLASE; MOSAPRIDE CITRATE; OLOPATADINE; OXIDOREDUCTASE; PENCICLOVIR; PHENELZINE; POLYAMINE OXIDASE; PROCARBAZINE; PROPRANOLOL; SULINDAC SULFIDE; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANTHINE OXIDASE; XENOBIOTIC AGENT;

AEROBIC METABOLISM; ARTICLE; CYSTIC FIBROSIS; DEPRESSION; DETOXIFICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME POLYMORPHISM; HUMAN; METABOLITE; NONHUMAN; PARKINSON DISEASE; XENOBIOTIC METABOLISM;

ANIMALS; ENZYMES; FLAVIN-ADENINE DINUCLEOTIDE; FLAVINS; HUMANS; MIXED FUNCTION OXYGENASES; MONOAMINE OXIDASE; OXIDATION-REDUCTION; XENOBIOTICS;

EID: 79551580339     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharma.2010.10.004     Document Type: Article

References (30)

1. Strolin Benedetti M., Whomsley R., Baltes E. Involvement of enzymes other than CYPs in the oxidative metabolism of xenobiotics. Expert Opin Drug Metab Toxicol 2006, 2:895-921.
2. Beedham C. The role of non-P450 enzymes in drug oxidation. Pharm World Sci 1997, 19:255-263.
3. Cashman J.R. Role of flavin-containing monooxygenase in drug development. Expert Opin Drug Metab Toxicol 2008, 4:1507-1521.
4. Motika M.S., Zhang J., Cashman J.R. Flavin-containing monooxygenase 3 and human disease. Expert Opin Drug Metab Toxicol 2007, 3:831-845.
5. Krueger S.K., Williams D.E. Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. Pharmacol Ther 2005, 106:357-387.
6. Cashman J.R. Some distinctions between flavin-containing and cytochrome P450 monooxygenases. Biochem Biophys Res Commun 2005, 338:599-604.
7. Park S.B., Jacob P., Benowitz N.L., Cashman J.R. Stereoselective metabolism of (S)-(-)-nicotine in humans: formation of trans-S-nicotine N-1'-oxide. Chem Res Toxicol 1993, 6:880-888.
8. Mwenifumbo J.C., Tyndale R.F. Molecular genetics of nicotine metabolism. Nicotine Psychopharmacology. Handbook of experimental pharmacology 192 2009, 235-259. Springer-Verlag, Berlin, Heidelberg. J.E. Henningfield (Ed.).
9. Mushiroda T., Douya R., Takahara E., Nagata O. The involvement of flavin-containing monooxygenase but not CYP3A4 in metabolism of itopride hydrochloride, a gastroprokinetic agent: comparison with cisapride and mosapride citrate. Drug Metab Dispos 2000, 28:1231-1237.
10. Rashidi M.R., Nazemiyeh H. Inhibitory effects of flavonoids on molybdenum hydroxylases activity. Expert Opin Drug Metab Toxicol 2010, 6:133-152.
11. Nishino T. The conversion of xanthine dehydrogenase to xanthine oxidase and the role of the enzyme in reperfusion injury. J Biochem 1994, 116:1-6.
12. Kitamura S., Sugihara K., Ohta S. Drug-metabolizing ability of molybdenum hydroxylases. Drug Metab Pharmacokinet 2006, 21:83-98.
13. Garattini E., Mendel R., Romao M.J., Wright R., Terao M. Mammalian molybdo-flavoenzymes, an expanding family of proteins: structure, genetics, regulation, function and pathophysiology. Biochem J 2003, 372:15-32.
14. Hamelin B.A., Xu K., Vallé F., Manseau L., Richer M., Lebel M. Caffeine metabolism in cystic fibrosis: enhanced xanthine oxidase activity. Clin Pharmacol Ther 1994, 56:521-529.
15. Beedham C. Molybdenum hydroxylases. Enzyme systems that metabolise drugs and other xenobiotics 2002, 147-187. John Wiley & Sons, Baffins Lane, Chichester. C. Ioannides (Ed.).
16. Strolin Benedetti M., Tipton K.F., Whomsley R. Amine oxidases and monooxygenases in the in vivo metabolism of xenobiotic amines in humans: has the involvement of amine oxidases been neglected?. Fundam Clin Pharmacol 2007, 21:467-479.
17. Wang Y., Devereux W., Woster P.M., Stewart T.M., Hacker A., Casero R.A. Cloning and characterization of a human polyamine oxidase that is inducible by polyamine analogue exposure. Cancer Res 2001, 61:5370-5373.
18. Gong B., Boor P.J. The role of amine oxidases in xenobiotic metabolism. Expert Opin Drug Metab Toxicol 2006, 2:559-571.
19. Strolin Benedetti M., Tipton K.F. Monoamine oxidases and related amine oxidases as phase I enzymes in the metabolism of xenobiotics. J Neural Transm 1998, 52(Suppl):149-171.
20. Haas M., Kubler W. Nicotine and sympathetic neurotransmission. Cardiovasc Drugs Ther 1997, 10:657-665.
21. Fowler J.S., Logan J., Wang G.J., Volkow N.D., Telang F., Zhu W., et al. Comparison of monoamine oxidase A in peripheral organs in nonsmokers and smokers. J Nucl Med 2005, 46:1414-1420.
22. Strolin Benedetti M. Biotransformation of xenobiotics by amine oxidases. Fundam Clin Pharmacol 2001, 15:75-84.
23. Tipton K.F., Strolin Benedetti M. Amine oxidases in the metabolism of xenobiotics. Enzyme systems that metabolise drugs and other xenobiotics 2002, 95-146. John Wiley & Sons, Baffins Lane, Chichester. C. Ioannides (Ed.).
24. Strolin Benedetti M., Tipton K.F., Whomsley R., Baltes E. Factors affecting the relative importance of amine oxidases and monooxygenases in the in vivo metabolism of xenobiotic amines in humans. J Neural Transm 2007, 114:787-791.
25. Suzuki O., Matsumoto T., Katsumata Y. Determination of polyamine oxidase activities in human tissues. Experientia 1984, 40:838-839.
26. Ferrante A., Storer R.J., Cleland L.J. Polyamine oxidase activity in rheumatoid arthritis synovial fluid. Clin Exp Immunol 1990, 80:373-375.
27. Chemuturi N.V., Donovan M.D. Metabolism of dopamine by the nasal mucosa. J Pharm Sci 2006, 95:2507-2515.
28. Poggesi I., Strolin Benedetti M., Whomsley R., Le Lamer S., Molimard M., Watelet J.B. Pharmacokinetics in special populations. Drug Metab Rev 2009, 41(Special Issue):422-454.
29. Chen X.Y., Zhong D.F., Duan J.L., Yan B.X. LC-MS-MS analysis of 2-pyridylacetic acid, a major metabolite of betahistine: application to a pharmacokinetic study in healthy volunteers. Xenobiotica 2003, 33:1261-1271.
30. Strolin Benedetti M., Allievi C., Cocchiara G., Pevarello P., Dostert P. Involvement of FAD-dependent polyamine oxidase in the metabolism of milacemide in the rat. Xenobiotica 1992, 22:191-197.